Arabian International Healthcare Holding Company SJSC

Arabian International Healthcare Holding Company SJSC maintains a debt-to-equity ratio of 1.22, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 1.47, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of SAR 25,150,460 supports operational flexibility, though operating cash flow of SAR 1,611,820 is relatively low. Profitability metrics show a return on equity of 6.46% and a return on assets of 1.77%, both below the industry median for Advanced Medical Equipment & Technology. The company's operating margin is 8.67% (SAR 73,046,300 operating income on SAR 842,213,540 revenue), which is lower than the median for its industry, indicating room for improvement in cost control and pricing power. The company operates in three segments: Project and medical equipment-based business, Consumable business, and Clinical and pharmaceutical business. Revenue concentration data is not available in the input, but the company's geographic exposure is entirely within Saudi Arabia, making it sensitive to local healthcare policy and economic conditions. Outlook data indicates a projected revenue growth of 12% for the current fiscal year and 8% for the next fiscal year. Historical revenue growth has been moderate, with the company reporting SAR 842,213,540 in the latest period. The growth trajectory is supported by the expansion of healthcare infrastructure in Saudi Arabia, a key driver for the industry. Risk factors include a medium liquidity risk due to the current ratio of 1.47 and a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance. However, the company's capital structure is leveraged, with long-term debt of SAR 444,262,750, which could increase financial risk if interest rates rise. Recent events include the company's continued focus on expanding its medical equipment and consumable businesses. No significant regulatory or legal events were disclosed in the latest filings, but the company remains subject to the evolving healthcare regulations in Saudi Arabia.